key: cord-0851147-3k92binn authors: Anand, Sai Priya; Prévost, Jérémie; Richard, Jonathan; Perreault, Josée; Tremblay, Tony; Drouin, Mathieu; Fournier, Marie-Josée; Lewin, Antoine; Bazin, Renée; Finzi, Andrés title: High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples date: 2020-10-20 journal: bioRxiv DOI: 10.1101/2020.10.20.346783 sha: 7f985fad3ceb09faf525d7e2e9cc7bb6b5ca9c55 doc_id: 851147 cord_uid: 3k92binn Background The SARS-CoV-2 virus is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing more than a million deaths. The SARS-CoV-2 Spike glycoproteins mediate viral entry and represent the main target for antibody responses. Humoral responses were shown to be important for preventing and controlling infection by coronaviruses. A promising approach to reduce the severity of COVID-19 is the transfusion of convalescent plasma. However, longitudinal studies revealed that the level of antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 Spike declines rapidly after the resolution of the infection. Study Design and Methods To extend this observation beyond the RBD domain, we performed a longitudinal analysis of the persistence of antibodies targeting the full-length SARS-CoV-2 Spike in the plasma from 15 convalescent donors. We generated a 293T cell line constitutively expressing the SARS-CoV-2 Spike and used it to develop a high-throughput flow cytometry-based assay to detect SARS-CoV-2 Spike specific antibodies in the plasma of convalescent donors. Results and Conclusion We found that the level of antibodies targeting the full-length SARS-CoV-2 Spike declines gradually after the resolution of the infection. This decline was not related to the number of donations, but strongly correlated with the decline of RBD-specific antibodies and the number of days post-symptom onset. These findings help to better understand the decline of humoral responses against the SARS-CoV-2 Spike and provide important information on when to collect plasma after recovery from active infection for convalescent plasma transfusion. The ongoing coronavirus disease 2019 pandemic is caused by the severe acute 34 respiratory syndrome coronavirus 2 (SARS-CoV-2) and as of October 2020, has caused over a 35 million deaths worldwide (https://www.worldometers.info/coronavirus/). The transfusion of 36 convalescent plasma for the treatment of respiratory infections caused by coronaviruses, such as 37 SARS-CoV-1, has been successful to improve patient outcome 1 . Its use has now been initiated 38 as an adjunctive therapy for patients with COVID-19 and several clinical trials are underway (for 39 example NCT04412486 and NCT04342182). Preliminary findings have suggested improvements 40 the generation of 293T cells stably expressing the SARS-CoV-2 Spike protein, transgenic 85 lentiviruses were produced in 293T using a third-generation lentiviral vector system. Briefly, 293T 86 cells were co-transfected with two packaging plasmids (pLP1 and pLP2), an envelope plasmid 87 (pSVCMV-IN-VSV-G) and a lentiviral transfer plasmid coding for a GFP-tagged SARS-CoV-2 88 Spike (pLV-SARS-CoV-2 S C-GFPSpark tag) (Sino Biological). Supernatant containing lentiviral 89 particles was used to transduce more 293T cells in presence of 5μg/mL polybrene. The 293T 90 cells stably expressing SARS-CoV-2 Spike (GFP+) were sorted by flow cytometry. based on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRII 98 cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.5.3 (Tree Star). 99 The seropositivity threshold was established using the following formula: (mean of all COVID-19 100 negative plasma + (3 standard deviation of the mean of all COVID-19 negative plasma) + inter-101 assay coefficient of variability). 102 103 Statistics were analyzed using GraphPad Prism version 8.4.3 (GraphPad, San Diego, CA). Every 105 dataset was tested for statistical normality and this information was used to apply the appropriate 106 (parametric or nonparametric) statistical test. P values < 0.05 were considered significant; 107 significance values are indicated as * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001. To develop a high-throughput flow cytometry assay able to detect anti-SARS-CoV-2 S antibodies 111 in plasma from convalescent donors, we generated a cell line stably expressing the full-length S 112 glycoprotein. Third-generation transgenic lentiviruses encoding for SARS-CoV-2 S were used to 113 transduce 293T cells. Since the S glycoprotein is fused to a C-terminal GFP tag, 293T-Spike cells 114 were sorted by flow cytometry based on GFP expression. The presence of cell-surface S was 115 confirmed using the anti-RBD CR3022 monoclonal Ab and plasma from SARS-CoV-2 infected 116 individuals. Specificity was confirmed using pre-pandemic healthy donor plasma ( Figure 1A ). For 117 our high-throughput flow cytometry-based assay, parental 293T and 293T-Spike cells were mixed 118 at an equal ratio and incubated with plasma from convalescent donors. Spike-specific antibodies 119 were detected by adding a fluorescent anti-human IgG (H+L) secondary antibody. The signal was 120 measured by flow cytometry and background signal measured on parental 293T cells (GFP 121 negative) was subtracted for specificity. Signal obtained with plasma from 10 COVID-19 negative 122 donors were used to define a limit of detection for seropositivity ( Figure 1B , C). 123 124 Recently, a longitudinal analysis was performed to measure the RBD-specific antibody response 126 in convalescent plasma from 33 to 114 days post-symptom onset using a semi-quantitative ELISA 127 18 . This cohort consisted of 11 males and 4 females (median age of 56 years old) and plasma was 128 donated at least 4 times. A decrease in RBD-specific antibody titers between the first and last 129 donations was observed for all 15 donors tested and this decline was shown to depend on time 130 post-recovery but not on the number of donations. To extend this observation beyond the RBD 131 domain, we used our high-throughput flow-cytometry based assay using the 293T-Spike cells to 132 measure the persistence of antibodies targeting the full-length SARS-CoV-2 Spike in these 133 convalescent plasma samples. Antibodies against S also decreased over time in these plasma 134 samples, with the decrease being significant ~74 days post-symptom onset onwards (Figure 2A) . 135 This finding was corroborated using a previously characterized flow-cytometry method to quantify 136 SARS-CoV-2 Spike-specific antibodies using 293T cells transiently transfected with a plasmid 137 encoding the full-length Spike 10,11,19-21 ( Figure 2B ), and the MFI obtained from both these methods 138 correlated significantly (r = 0.9207, p<0.0001) ( Figure 2C ). Results obtained with both flow 139 cytometry assays, using transduced or transfected 293T cells, also positively correlated with the 140 levels of RBD-specific antibodies as quantified by ELISA in the recently published study using the 141 same cohort 18 ( Figure 2C ). Of note, the decline of total anti-Spike antibodies did not correlate The authors thank the CRCHUM Flow Cytometry Platform for technical assistance. The authors 161 are grateful to the convalescent plasma donors who participated in this study and the Héma-162 Québec team involved in convalescent donor recruitment and plasma collection. We thank Dr. The authors declare no competing interests. Use of convalescent plasma therapy in SARS patients in Hong Kong Effectiveness of convalescent plasma therapy in 219 severe COVID-19 patients Treatment of 5 Critically Ill Patients With COVID-19 223 With Convalescent Plasma Treatment with 225 convalescent plasma for COVID-19 patients in Wuhan Use of convalescent plasma in 229 hospitalized patients with COVID-19: case series Structure, Function, 231 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein SARS-CoV-2 Cell 234 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 235 Inhibitor Convalescent plasma in Covid-19: Possible mechanisms of 239 action Liu 243 Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients 244 With Severe and Life-threatening COVID-19: A Randomized Clinical Trial Cross-251 sectional evaluation of humoral responses against SARS-CoV-2 Spike Decline of 256 Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals Convergent antibody responses to SARS-265 CoV-2 in convalescent individuals Human neutralizing antibodies elicited by SARS-CoV-2 infection. 269 Isolation of potent SARS-CoV-2 neutralizing antibodies and 275 protection from disease in a small animal model Potent neutralizing antibodies 279 against multiple epitopes on SARS-CoV-2 spike Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of 286 severity The landscape of antibody binding to SARS-CoV-2 Waning of SARS-CoV-2 RBD antibodies in 292 longitudinal convalescent plasma samples within four months after symptom onset. 293 Blood 2020 Pre-existing 301 and de novo humoral immunity to SARS-CoV-2 in humans Ultrapotent human antibodies protect against SARS-CoV-2 challenge 310 via multiple mechanisms Rapid response flow cytometric assay for the detection of antibody responses to 314 SARS-CoV-2